Atyr PHARMA INC (NASDAQ:ATYR – Free Report) – Investment analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Atyr PHARMA in a report issued on Thursday ...

Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors cautious. See why ATYR stock is a Hold.

This very-high-yielding FTSE 100 heavyweight has fallen a long way since its 2017 peak, which has left it looking extremely undervalued, in my view. The post Investors considering a £9,000 investment ...

However, when multiple insiders purchase stock, like in aTyr Pharma, Inc.'s (NASDAQ:ATYR) instance, it's good news for shareholders. Although we don't think shareholders should simply follow ...

Analyst Price Forecast Suggests 413.85% Upside As of December 23, 2024, the average one-year price target for aTyr Pharma is $20.40/share. The forecasts range from a low of $9.09 to a high of $36.75.

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for interstitial lung diseases, a Phase 3 trial in ...

Today's pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...